1,25-Dihydroxyvitamin D and the Vitamin D Receptor Gene Polymorphism Apa1 Influence Bone Mineral Density in Primary Hyperparathyroidism

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Christensen, Monika H E ^a,b   Apalset, Ellen M ^a,b   Nordbø, Yngve ^b   Varhaug, Jan Erik ^a,b   Mellgren, Gunnar ^a,b   Lien, Ernst A ^a,b  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; VITAMIN D RECEPTOR;

ADULT; APA1 GENE; ARTICLE; BONE DENSITY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; FEMUR NECK; GENE; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; PRIMARY HYPERPARATHYROIDISM; RADIUS; SINGLE NUCLEOTIDE POLYMORPHISM; VITAMIN BLOOD LEVEL;

ADULT; AGED; ALLELES; BONE AND BONES; BONE DENSITY; CROSS-SECTIONAL STUDIES; FEMALE; GENOTYPE; HUMANS; HYPERPARATHYROIDISM, PRIMARY; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; RECEPTORS, CALCITRIOL; VITAMIN D;

EID: 84873888570     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0056019     Document Type: Article

References (49)

1. Fraser WD, (2009) Hyperparathyroidism. Lancet 374: 145-158.
2. Bollerslev J, Jansson S, Mollerup CL, Nordenstrom J, Lundgren E, et al. (2007) Medical observation, compared with parathyroidectomy, for asymptomatic primary hyperparathyroidism: a prospective, randomized trial. J Clin Endocrinol Metab 92: 1687-1692.
3. Vestergaard P, Mollerup CL, Frokjaer VG, Christiansen P, Blichert-Toft M, et al. (2000) Cohort study of risk of fracture before and after surgery for primary hyperparathyroidism. BMJ 321: 598-602.
4. Omdahl JL, Morris HA, May BK, (2002) Hydroxylase enzymes of the vitamin D pathway: expression, function, and regulation. Annu Rev Nutr 22: 139-166.
5. van Driel M, Koedam M, Buurman CJ, Hewison M, Chiba H, et al. (2006) Evidence for auto/paracrine actions of vitamin D in bone: 1alpha-hydroxylase expression and activity in human bone cells. FASEB J 20: 2417-2419.
6. Goltzman D, Miao D, Panda DK, Hendy GN, (2004) Effects of calcium and of the Vitamin D system on skeletal and calcium homeostasis: lessons from genetic models. J Steroid Biochem Mol Biol 89-90: 485-489.
7. Lips P, (2001) Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocr Rev 22: 477-501.
8. Boudou P, Ibrahim F, Cormier C, Sarfati E, Souberbielle JC, (2006) A very high incidence of low 25 hydroxy-vitamin D serum concentration in a French population of patients with primary hyperparathyroidism. J Endocrinol Invest 29: 511-515.
9. Moosgaard B, Vestergaard P, Heickendorff L, Melsen F, Christiansen P, et al. (2005) Vitamin D status, seasonal variations, parathyroid adenoma weight and bone mineral density in primary hyperparathyroidism. Clin Endocrinol (Oxf) 63: 506-513.
10. Jones G, Prosser DE, Kaufmann M (2011) 25-Hydroxyvitamin D-24-hydroxylase (CYP24A1): Its important role in the degradation of vitamin D. Arch Biochem Biophys.
11. Tashiro K, Abe T, Oue N, Yasui W, Ryoji M, (2004) Characterization of vitamin D-mediated induction of the CYP 24 transcription. Mol Cell Endocrinol 226: 27-32.
12. Holick MF, (1995) Environmental factors that influence the cutaneous production of vitamin D. Am J Clin Nutr. 61: 638S-645S.
13. Macdonald HM, Mavroeidi A, Barr RJ, Black AJ, Fraser WD, et al. (2008) Vitamin D status in postmenopausal women living at higher latitudes in the UK in relation to bone health, overweight, sunlight exposure and dietary vitamin D. Bone. 42: 996-1003.
14. Christensen MH, Lien EA, Hustad S, Almas B, (2010) Seasonal and age-related differences in serum 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D and parathyroid hormone in patients from Western Norway. Scand J Clin Lab Invest 70: 281-286.
15. Hunter D, De Lange M, Snieder H, MacGregor AJ, Swaminathan R, et al. (2001) Genetic contribution to bone metabolism, calcium excretion, and vitamin D and parathyroid hormone regulation. J Bone Miner Res 16: 371-378.
16. Norman AW, Bishop JE, Bula CM, Olivera CJ, Mizwicki MT, et al. (2002) Molecular tools for study of genomic and rapid signal transduction responses initiated by 1 alpha,25(OH)(2)-vitamin D(3). Steroids 67: 457-466.
17. Fang Y, van Meurs JB, Rivadeneira F, van Schoor NM, van Leeuwen JP, et al. (2007) Vitamin D receptor gene haplotype is associated with body height and bone size. J Clin Endocrinol Metab 92: 1491-1501.
18. Grimnes G, Almaas B, Eggen AE, Emaus N, Figenschau Y, et al. (2010) Effect of smoking on the serum levels of 25-hydroxyvitamin D depends on the assay employed. Eur J Endocrinol 163: 339-348.
19. Holm PI, Ueland PM, Kvalheim G, Lien EA, (2003) Determination of choline, betaine, and dimethylglycine in plasma by a high-throughput method based on normal-phase chromatography-tandem mass spectrometry. Clin Chem 49: 286-294.
20. Levey AS, Coresh J, Greene T, Marsh J, Stevens LA, et al. (2007) Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem 53: 766-772.
21. Ramos-Lopez E, Kahles H, Weber S, Kukic A, Penna-Martinez M, et al. (2008) Gestational diabetes mellitus and vitamin D deficiency: genetic contribution of CYP27B1 and CYP2R1 polymorphisms. Diabetes Obes Metab 10: 683-685.
22. Shen H, Bielak LF, Ferguson JF, Streeten EA, Yerges-Armstrong LM, et al. (2010) Association of the vitamin D metabolism gene CYP24A1 with coronary artery calcification. Arterioscler Thromb Vasc Biol 30: 2648-2654.
23. Simon KC, Munger KL, Kraft P, Hunter DJ, De Jager PL, et al. (2011) Genetic predictors of 25-hydroxyvitamin D levels and risk of multiple sclerosis. J Neurol 258: 1676-1682.
24. Uitterlinden AG, Ralston SH, Brandi ML, Carey AH, Grinberg D, et al. (2006) The association between common vitamin D receptor gene variations and osteoporosis: a participant-level meta-analysis. Ann Intern Med 145: 255-264.
25. Wang TJ, Zhang F, Richards JB, Kestenbaum B, van Meurs JB, et al. (2010) Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet 376: 180-188.
26. Russell RG, Espina B, Hulley P, (2006) Bone biology and the pathogenesis of osteoporosis. Curr Opin Rheumatol 18Suppl 1: S3-10.
27. Langsetmo L, Hitchcock CL, Kingwell EJ, Davison KS, Berger C, et al. (2012) Physical activity, body mass index and bone mineral density-associations in a prospective population-based cohort of women and men: the Canadian Multicentre Osteoporosis Study (CaMos). Bone 50: 401-408.
28. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, et al. (2007) PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81: 559-575.
29. Moosgaard B, Christensen SE, Vestergaard P, Heickendorff L, Christiansen P, et al. (2008) Vitamin D metabolites and skeletal consequences in primary hyperparathyroidism. Clin Endocrinol (Oxf) 68: 707-715.
30. Ueno Y, Shinki T, Nagai Y, Murayama H, Fujii K, et al. (2003) In vivo administration of 1,25-dihydroxyvitamin D3 suppresses the expression of RANKL mRNA in bone of thyroparathyroidectomized rats constantly infused with PTH. J Cell Biochem 90: 267-277.
31. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, et al. (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93: 165-176.
32. Hsu H, Lacey DL, Dunstan CR, Solovyev I, Colombero A, et al. (1999) Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci U S A 96: 3540-3545.
33. Suda T, Ueno Y, Fujii K, Shinki T, (2003) Vitamin D and bone. J Cell Biochem 88: 259-266.
34. Silverberg SJ, Shane E, de la Cruz L, Dempster DW, Feldman F, et al. (1989) Skeletal disease in primary hyperparathyroidism. J Bone Miner Res 4: 283-291.
35. Rubin MR, Bilezikian JP, McMahon DJ, Jacobs T, Shane E, et al. (2008) The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years. J Clin Endocrinol Metab 93: 3462-3470.
36. Christiansen P, Steiniche T, Brockstedt H, Mosekilde L, Hessov I, et al. (1993) Primary hyperparathyroidism: iliac crest cortical thickness, structure, and remodeling evaluated by histomorphometric methods. Bone 14: 755-762.
37. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, et al. (2011) Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96: 1911-1930.
38. IOM (2010) Dietary reference intakes for calcium and vitamin D. National Academies Press: Institute of Medicine.
39. Lips P, Bouillon R, van Schoor NM, Vanderschueren D, Verschueren S, et al. (2010) Reducing fracture risk with calcium and vitamin D. Clin Endocrinol (Oxf). 73: 277-285.
40. Bischoff-Ferrari HA, (2008) Optimal serum 25-hydroxyvitamin D levels for multiple health outcomes. Adv Exp Med Biol 624: 55-71.
41. Bilezikian JP, Khan AA, Potts JT Jr, (2009) Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. J Clin Endocrinol Metab 94: 335-339.
42. Bollerslev J, Marcocci C, Sosa M, Nordenstrom J, Bouillon R, et al. (2011) Current evidence for recommendation of surgery, medical treatment and vitamin D repletion in mild primary hyperparathyroidism. Eur J Endocrinol 165: 851-864.
43. Rao RR, Randeva H, Sankaranarayanan S, Narashima M, Mölig M, et al. (2012) Prolonged treatment with vitamin D in postmenopausal women with primary hyperparathyroidism. Endocrine connections 01: 13-21.
44. Grey A, Lucas J, Horne A, Gamble G, Davidson JS, et al. (2005) Vitamin D repletion in patients with primary hyperparathyroidism and coexistent vitamin D insufficiency. J Clin Endocrinol Metab 90: 2122-2126.
45. Kantorovich V, Gacad MA, Seeger LL, Adams JS, (2000) Bone mineral density increases with vitamin D repletion in patients with coexistent vitamin D insufficiency and primary hyperparathyroidism. J Clin Endocrinol Metab 85: 3541-3543.
46. Bollerslev J, Gram J, Nielsen HK, Brixen K, Storm T, et al. (1991) Effect of a short course of 1,25-dihydroxyvitamin D3 on biochemical markers of bone remodeling in adult male volunteers. Bone 12: 339-343.
47. Mosekilde L, Charles P, Lindegreen P, (1989) Determinants for serum 1,25-dihydroxycholecalciferol in primary hyperparathyroidism. Bone Miner 5: 279-290.
48. Dundar U, Solak M, Kavuncu V, Ozdemir M, Cakir T, et al. (2009) Evidence of association of vitamin D receptor Apa I gene polymorphism with bone mineral density in postmenopausal women with osteoporosis. Clin Rheumatol 28: 1187-1191.
49. Flicker L, Hopper JL, Rodgers L, Kaymakci B, Green RM, et al. (1995) Bone density determinants in elderly women: a twin study. J Bone Miner Res 10: 1607-1613.